The Court has preliminarily approved three proposed class action settlements in the Valsartan, Losartan, and Irbesartan Products Liability Litigation (MDL 1:19-md-02875) filed in the US District Court for the District of New Jersey. Kanner & Whiteley’s Conlee Whiteley serves as co-lead Counsel in the MDL and has been appointed as class counsel for the earlier certified litigation classes and for these class settlements. The settlements reflect months of careful negotiation and extensive documentation prepared and filed by our team and provide an important path toward fair compensation for individuals affected by contaminated blood-pressure medications.
The MDL consolidates claims from plaintiffs who allege they were exposed to NDMA and NDEA which are carcinogens found in certain blood-pressure medications. This litigation involves personal-injury claims, and class-wide economic loss and medical monitoring claims, making it one of the largest pharmaceutical MDLs in recent years.
Class notice will be disseminated shortly, and a fairness hearing has been scheduled for June 30, 2026.
The court’s orders approving each of the three settlements are linked below: